How do I safely stop taking Lexapro (escitalopram)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Safely Discontinuing Lexapro (Escitalopram)

Yes, you absolutely need to wean off Lexapro—abrupt discontinuation can cause significant withdrawal symptoms and should be avoided except in emergency situations. 1

Why Gradual Tapering is Essential

A gradual dose reduction rather than abrupt cessation is recommended whenever possible to minimize discontinuation symptoms. 1 Stopping SSRIs like Lexapro suddenly can trigger antidepressant discontinuation syndrome (ADS), characterized by:

  • Dizziness, electric shock-like sensations, and paresthesias 1, 2
  • Flu-like symptoms including headache, sweating, and nausea 1, 2
  • Mood disturbances including anxiety, irritability, and confusion 1
  • Sleep disturbances and restlessness 1
  • These symptoms can last from days to months depending on the individual 2

Recommended Tapering Approach

The FDA label for escitalopram explicitly states that patients should be monitored for discontinuation symptoms and that gradual dose reduction is preferred over abrupt cessation. 1 If intolerable symptoms occur following a dose decrease, resuming the previously prescribed dose should be considered, followed by an even more gradual taper. 1

Tapering Duration and Strategy

Current evidence suggests that tapers should occur over weeks to months, not the traditional 2-4 weeks recommended in older guidelines. 3, 4, 2 The most recent research indicates:

  • Short tapers (2-4 weeks) show minimal benefit over abrupt discontinuation and are often not tolerated by patients 4
  • Tapers extending over months and reaching doses much lower than minimum therapeutic doses have shown greater success in reducing withdrawal symptoms 4
  • Hyperbolic (exponential) tapering—where each new dose is approximately 90% of the previous dose—may be more effective than linear tapering 4

A practical approach involves:

  • Reducing the dose by small increments (e.g., 10% of the current dose, not the original dose) 5, 4
  • Waiting 1-2 weeks between dose reductions for shorter half-life SSRIs like escitalopram 5
  • Slowing the taper further in the low-dose range, as receptor occupancy changes are more dramatic at lower doses 4
  • Continuing to very small doses (potentially 1-2 mg or less) before complete cessation 4

Managing Withdrawal Symptoms

If discontinuation symptoms develop despite tapering, restart the previous dose and then taper even more slowly. 1, 2 Additional symptomatic management may include:

  • Clonidine for autonomic symptoms 5
  • Symptomatic treatment for specific complaints (e.g., antiemetics for nausea) 2
  • Reassurance and patient education that symptoms are temporary 6

Special Considerations

Escitalopram (along with paroxetine, fluvoxamine, and sertraline) has been specifically associated with discontinuation syndrome. 5 This makes careful tapering particularly important for this medication.

Patient education is critical throughout the discontinuation process. 6 Patients should understand:

  • What symptoms to expect and that they are temporary, not a return of depression 6
  • The importance of not stopping abruptly on their own 1
  • When to contact their healthcare provider 1

When Tapering May Not Be Appropriate

The only exceptions to gradual tapering are extreme cases such as:

  • Confirmed medication diversion 5
  • Serious medical toxicity requiring immediate cessation 5
  • Serotonin syndrome or severe allergic reactions 1

Even in these situations, there may be risks associated with abrupt discontinuation that must be weighed against the emergency. 5

Monitoring During Discontinuation

Close observation and support during the taper are critical, with clinician availability to treat symptoms and manage concerns. 5 Contact (in-person or by telephone) should occur regularly after dose reductions to assess for withdrawal symptoms and provide support. 5

References

Research

Discontinuing antidepressants: Pearls and pitfalls.

Cleveland Clinic journal of medicine, 2022

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A review of the management of antidepressant discontinuation symptoms.

Therapeutic advances in psychopharmacology, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.